Home » Authors » James Etheridge

Articles by James Etheridge

French Start-Up ObeTherapy Gains Funds For Obesity Work

Nov. 27, 2002

By James Etheridge

French Start-Up ObeTherapy Gains Funds For Obesity Work

Nov. 27, 2002

By James Etheridge

MAT Biotech Secures 1.25M For Antibody Developmen

Nov. 27, 2002

By James Etheridge

Synt:em, Probiodrug Partner To Develop Multiple Sclerosis Drug

Nov. 20, 2002

By James Etheridge

GenOway, CopyRat Collaborate To Develop Rat Disease Models

Nov. 20, 2002

By James Etheridge

Synt:em, Probiodrug Partner To Develop Multiple Sclerosis Drug

Nov. 20, 2002

By James Etheridge

GenOway, CopyRat Collaborate To Develop Rat Disease Models

Nov. 20, 2002

By James Etheridge

Serono Acquires 92 Percent of Genset, Collaborates with IVAX

Nov. 13, 2002

By James Etheridge

Serono Acquires 92 Percent of Genset, Collaborates with IVAX

Nov. 13, 2002

By James Etheridge

Avidis Closing EUR1.7M Round To Develop Peptides Technology

Nov. 6, 2002

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.